Please ensure Javascript is enabled for purposes of website accessibility

Happy (Sniffle) Holidays (Cough)

By Brian Lawler – Updated Nov 15, 2016 at 5:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's flu season again.

Tis the season to be jolly, and also for the flu to strike millions of people. The virus may not be nearly as dangerous and lethal as it used to be -- the disease kills 300,000 to 500,000 people worldwide every year, but the 1918 flu pandemic killed 50 million to 100 million people. However, with fears over the avian flu, and the stockpiling of millions of doses of drugs like Roche's Tamiflu to treat the various forms of the disease, there are billions of dollars to be made by the pharmaceutical companies that are treating and preventing the flu.

Not only does treating the flu prevent people from having to deal with the runny noses and other symptoms of the infectious disease, but flu prevention can also save employers from the costs of lost productivity due to time off from work. According to the aptly named consulting firm Challenger, Gray, and Christmas, employees will miss 70 million days of work because of the flu, adding up to $10 billion in lost wages for companies as a result of paid sick leave.

The amount of these lost wages has led to a rapid growth in the market for influenza vaccines. In 2005, Sanofi-Aventis (NYSE:SNY) had sales of $819 million for its flu vaccines, up 29% over 2004; Chiron (now part of Novartis (NYSE:NVS)) sold $97 million worth of its flu vaccines in 2005 despite experiencing severe manufacturing issues for much of the year. The other player in this field is MedImmune (NASDAQ:MEDI); its FluMist product achieved only $21 million in 2005 sales, but a next-generation product named CAIV-T hopefully will be coming to the market sometime next year.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy .

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$38.40 (-1.87%) $0.73
Novartis AG Stock Quote
Novartis AG
NVS
$76.01 (-1.47%) $-1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.